American Recovery and Reinvestment Act (ARRA) Funding Supports Addition of Three Pediatric Cancers in TARGET Initiative

September 24, 2009

As part of the National Cancer Institute's American Recovery and Reinvestment Act (ARRA) funding to significantly enhance cancer research, the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative was awarded $25 million to expand research on the molecular basis of childhood cancers.

Each year, more than 10,000 children will be diagnosed with cancer. The Recovery Act funds will allow TARGET to further progress its research for two current TARGET projects on acute lymphoblastic leukemia (ALL) and neuroblastoma, and expand to include molecular characterization of three additional childhood cancers including acute myelogenous leukemia (AML), osteosarcoma and Wilms tumor. The funds will also be used to increase sequencing capacity to support the goals of the expanded program. Learn more about our TARGET collaborators and cancers selected for study.

Last updated: March 16, 2017